- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06776185
Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma
January 10, 2025 updated by: Chen Xiaoping
Recurrence Patterns and Cost-Effectiveness of Robotic-assisted, Laparoscopic, and Open Liver Resection in BCLC 0/A Hepatocellular Carcinoma:
This study aims to investigate the recurrence patterns and cost-effectiveness of robotic-assisted, laparoscopic, and open liver resections in patients with early-stage (BCLC 0/A) hepatocellular carcinoma.
By analyzing data from 3000 patients across 27 centers, the research evaluates recurrence-free survival, overall survival, and long-term economic impacts using metrics such as quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).
Findings will provide insights into optimal surgical approaches to improve patient outcomes and healthcare resource utilization.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Wuhan Tongji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This multicenter study included BCLC stage 0/A HCC patients who underwent RALR, LLR, or OLR across 27 centers from July 2017 to July 2019
Description
Inclusion Criteria:
- (1) HCC diagnosis confirmed by two independent radiologists using contrast-enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) combined with postoperative pathology; (2) BCLC stage 0 or A; and (3) curative liver resection
Exclusion Criteria:
- (1) concurrent malignancies in other organs; (2) diagnosis of combined hepatocellular-cholangiocarcinoma; (3) prior neoadjuvant or adjuvant treatment before liver resection; (4) recurrent HCC; (5) ruptured HCC; and (6) incomplete follow-up or missing data.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Robotic-assisted
RALR was conducted using a robotic platform, which allowed for precise dissection and 3D visualization.
Robotic arms equipped with advanced energy devices facilitated delicate maneuvers, particularly in deep or difficult-to-access segments.
A 3D liver model was displayed on the robotic console, enabling real-time reference during dissection.
As with LLR, intraoperative ultrasound refined the tumor boundaries, and the Pringle maneuver was selectively applied when necessary.
|
Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement.
Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
|
|
Laparoscopic
LLR was performed using standard laparoscopic instruments, with the surgeon directly manipulating instruments for tumor resection.
Intraoperative ultrasound was routinely used to confirm tumor boundaries and refine resection margins, particularly for tumors adjacent to major vascular structures.
During parenchymal transection, energy devices such as laparoscopic bipolar coagulators or ultrasonic scalpels were used to minimize blood loss.
The Pringle maneuver was available as needed to control bleeding.
|
Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement.
Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
|
|
Open Liver Resection
Open liver resection was typically performed through a right subcostal incision, extended to the midline if necessary to enhance liver access.
The liver was mobilized by dividing surrounding ligaments, including the falciform, coronary, and triangular ligaments, to ensure optimal exposure of the tumor.
Intraoperative ultrasound was used to confirm the exact tumor location, delineate resection margins, and detect any additional satellite nodules or vascular invasion not identified preoperatively.
The Pringle maneuver, involving intermittent clamping of the portal triad, was selectively applied to control blood loss during parenchymal transection.
Based on tumor characteristics, anatomical resections aimed to remove full segments, while non-anatomical resections focused on achieving negative margins (R0 resection) with minimal liver removal.
Large tumors, central lesions, or cases requiring complex vascular reconstruction were typically managed with the open approach due to its direct a
|
Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement.
Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrence-free Surival
Time Frame: 2017-01-01--2024-01-01
|
2017-01-01--2024-01-01
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2022
Primary Completion (Actual)
November 15, 2024
Study Completion (Actual)
November 15, 2024
Study Registration Dates
First Submitted
January 10, 2025
First Submitted That Met QC Criteria
January 10, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 10, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RLOCE-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC - Hepatocellular Carcinoma
-
Zhejiang Haichang Biotech Co., Ltd.Not yet recruitingAdvanced Hepatocellular Carcinoma (HCC)
-
Ahmed Karam HelmyNot yet recruitingAdvanced Hepatocellular Carcinoma (HCC)Egypt
-
Fudan UniversityRecruitingAdvanced Hepatocellular Carcinoma (HCC)China
-
Bangladesh Medical UniversityRecruitingUnresectable Hepatocellular Carcinoma (HCC)Bangladesh
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingAdvanced Hepatocellular Carcinoma (HCC)
-
Zhejiang UniversityNot yet recruitingUnresectable Hepatocellular Carcinoma (HCC)China
-
Tongji HospitalCompletedHuge Hepatocellular Carcinoma (HCC) (>10cm)China
-
Qiang XuActive, not recruitingHepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma (HCC) PrognosisChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruitingHepatocellular Carcinoma (HCC) | Unresectable Hepatocellular Carcinoma (HCC) | Liver Cancer AdultChina
-
Shen LinMETiS PharmaceuticalsRecruitingHepatocellular Carcinoma (HCC) | Liver Cancer, Adult | HCC - Hepatocellular Carcinoma | Metastatic Liver CancersChina
Clinical Trials on Liver Surgery
-
Tongji HospitalThe First Affiliated Hospital of Anhui Medical University; The Affiliated Nanjing... and other collaboratorsNot yet recruiting
-
Fudan UniversityCompletedColorectal Cancer | Liver Metastases
-
Amsterdam UMC, location VUmcUMC Utrecht; General Hospital Groeninge; Intuitive Surgical; Fondazione Poliambulanza...Not yet recruitingLiver Diseases | Biliary Tract Diseases | Liver Metastases | Liver Neoplasm | Biliary Tract Neoplasms | Liver Cancer | Biliary Tract Cancer
-
Navari Surgical ABNot yet recruiting
-
University of MilanCompletedHepatocellular Carcinoma | Surgery | Cholangiocarcinoma | Liver Carcinoma
-
Washington University School of MedicineTerminated
-
University of MilanCompletedHepatectomy | Cirrhosis | Hepatecellular CarcinomaItaly
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedLiver Cancer | Hepatobiliary Tract Adenomas and CarcinomasUnited States
-
Asian Institute of Gastroenterology, IndiaRecruitingCHRONIC LIVER DISEASEIndia
-
University of MilanCompletedHepatectomy | Surgery | Liver Tumors | Liver Resection